MedTrace Logo

An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001

NCT07378579 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-01-30

No results posted yet for this study

Summary

This a phase 1, partially blinded, randomized, crossover study to determine the pharmacokinetics (PK) and QT/QTc interval of study drug (ESK-001) in healthy volunteer participants,

Conditions

  • Healthy Volunteer

Interventions

DRUG

ESK-001

Single oral dose of ESK-001 in participants

DRUG

Moxifloxacin (400 mg)

positive control

DRUG

Placebo

ESK-001-matched placebo

Sponsors & Collaborators

  • Alumis Inc

    lead INDUSTRY

Principal Investigators

  • Jorn Drappa, MD, Ph.D. · Alumis Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-21
Primary Completion
2024-08-31
Completion
2024-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07378579 on ClinicalTrials.gov